Abstract 618P
Background
Renal Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) among adults is an extremely rare malignancy. Accurate diagnosis mandates detailed immunohistochemistry (IHC) and molecular characterization. There is limited data on the treatment of these patients. We present a clinicopathological and molecular profile of renal ES/PNET from a single South Indian tertiary referral center.
Methods
We conducted a retrospective study of adults with a histopathological diagnosis of renal ES/PNET treated at our center over the last 20 years. All patients had received a standard treatment protocol of VAC/IE. Principal outcomes were event-free survival (EFS), overall survival (OS) and adverse events during treatment.
Results
We included 25 patients with renal ES treated at our center from 2003-2023. 68% were male, with median age 29(18-53). 8(32%) had localised disease and 17(68%) had recurrent/metastatic disease; lung(36%) and bone(28%) were the common sites of metastases. Median tumour size was 13.5cm and renal vein/IVC thrombus was present in 11(55%) patients. IHC(done in 24 patients), showed CD99 +, NKX 2.2 + in 100% and FLI1 + in 93.7%. RT-PCR/FISH done in 15 patients revealed EWS-FLI1 translocations in 5 patients, 4 of which were Type 1. Nephrectomy was performed in 19 patients: 8 radical for non-metastatic and 11 palliative for metastatic disease. 16 received systemic therapy, the median number of cycles being 10(Range:2-16). 11 patients received concurrent radiation. Grade 3/4 anaemia, thrombocytopenia, neutropenia, and febrile neutropenia was seen in 1(6.6%),1(6.6%),8(50%) and 8(50%) patients respectively during VAC/IE. Only 50% of patients had long term follow up. Survival at 3 years is 64.3%(83% for localised disease, 57.3% for recurrent/metastatic).
Conclusions
This study represents a substantial cohort of adult patients with renal ES/PNET undergoing a unified treatment approach. Predominantly, tumors presented as extensive and locally aggressive with favourable survival for localised disease. While these observations offer valuable insights, the rarity of the disease underscores the need for larger, multicentric studies for more definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract